Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ metabolism
CD8 Antigens
/ metabolism
Drug Resistance, Neoplasm
Esophageal Neoplasms
/ drug therapy
Esophageal Squamous Cell Carcinoma
/ drug therapy
Female
Follow-Up Studies
Histocompatibility Antigens Class I
/ metabolism
Humans
Japan
Lymphocytes, Tumor-Infiltrating
/ metabolism
Male
Middle Aged
Nivolumab
/ administration & dosage
Survival Rate
Treatment Outcome
Tumor Burden
/ drug effects
CD8+ tumor-infiltrating lymphocyte
esophageal squamous cell carcinoma
long-term survival
nivolumab
programmed death-1
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
18
09
2019
revised:
02
02
2020
accepted:
18
02
2020
pubmed:
12
3
2020
medline:
2
6
2020
entrez:
12
3
2020
Statut:
ppublish
Résumé
The long-term efficacy of nivolumab in esophageal squamous cell carcinoma and its association with disease biomarkers are currently not well known. Therefore, we investigated the association in Japanese patients with treatment-refractory advanced esophageal cancer who participated in an open-label, single-arm, multicenter phase II study. Patients received nivolumab 3 mg/kg i.v. every 2 weeks until disease progression or unacceptable toxicity, and were followed up for 2 years after the initial dosing of the last patient. Archival tissue samples were collected before treatment and analyzed for programmed death ligand-1 (PD-L1) and CD8
Identifiants
pubmed: 32160365
doi: 10.1111/cas.14380
pmc: PMC7226206
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
CD8 Antigens
0
Histocompatibility Antigens Class I
0
Nivolumab
31YO63LBSN
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1676-1684Subventions
Organisme : Ono Pharmaceuticals
Organisme : Bristol-Myers Squibb
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Transl Med. 2012 Apr 10;10:70
pubmed: 22490302
Cancer Sci. 2020 May;111(5):1676-1684
pubmed: 32160365
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
ESMO Open. 2017 Mar 7;1(4):e000108
pubmed: 28861280
Cancer Immunol Res. 2014 Oct;2(10):981-7
pubmed: 24994597
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
J Biomed Sci. 2017 May 25;24(1):35
pubmed: 28545567
Sci Rep. 2017 May 18;7(1):2074
pubmed: 28522811
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
Breast Cancer Res. 2011;13(6):R126
pubmed: 22151962
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Clin Cancer Res. 2006 Aug 1;12(15):4641-4
pubmed: 16899613
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Clin Cancer Res. 2017 Sep 1;23(17):4970-4979
pubmed: 28864725
Oncol Lett. 2017 Jun;13(6):4818-4824
pubmed: 28599483
J Cancer. 2017 Jul 5;8(11):2018-2025
pubmed: 28819402
Lancet Oncol. 2017 May;18(5):631-639
pubmed: 28314688
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
J Gastrointest Oncol. 2015 Oct;6(5):561-9
pubmed: 26487950
JAMA Oncol. 2016 Jan;2(1):56-64
pubmed: 26469139
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Histopathology. 2011 Jun;58(7):1107-16
pubmed: 21707712